Tg Therapeutics shares fall 1.17% intraday after announcing 6-year BRIUMVI data at ECTRIMS meeting.

Tg Therapeutics, Inc. declined 1.17% in intraday trading, with the company announcing updated data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) at the 2025 ECTRIMS annual meeting. The data showed that 90% of multiple sclerosis patients were free from progression after 6 years of treatment, and there was no association between decreased immunoglobulin levels and risk of serious infections.